The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Netflix Inc. (NFLX): The streaming giant reported better-than-expected second-quarter earnings and raised its annual forecast ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.